<DOC>
	<DOCNO>NCT02702739</DOCNO>
	<brief_summary>The proportion HCV infect patient age 65 year Western country increase . This growth advent new antiviral therapy bring question real world efficacy safety combination Sofosbuvir Simeprevir ( SOF/SMV ) plus flat dose ribavirin ( RBV ) elderly patient compare young patient .</brief_summary>
	<brief_title>Sofosbuvir/Simeprevir Plus Flat Dose Ribavirin Genotype 1 Elderly HCV Cirrhotic Patients</brief_title>
	<detailed_description>The proportion HCV infect patient age 65 year Western country increase . This growth advent new antiviral therapy bring question real world efficacy safety combination Sofosbuvir Simeprevir ( SOF/SMV ) plus flat dose ribavirin ( RBV ) elderly patient ( Group II ) compare young patient ( Group I ) Multicenter , real world investigation study daily treatment SOF 400 mg + SMV 150 mg flat dose RBV 800 mg/day duration 12 week treatment na√Øve experience HCV genotype 1-infected patient compensate cirrhosis.To evaluate efficacy , tollerability safety SOF/SMV/RBV two different Group patient .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Naive experience patient genotype 1 compensated cirrhosis HIV hepatitis B infection , active hepatocellular carcinoma ( HCC ) , decompensated cirrhosis , history organ transplant , severe psychiatric disorder treatment drug show interaction antiviral treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>